284 related articles for article (PubMed ID: 25525605)
41. A Whole of Population, Multiuser Series of High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: Outcomes and Implications.
Bolton D; Ong K; Giles G; Severi G; Lawrentschuk N; Papa N; Troy A; Woo H; Millar J; Royce P
J Endourol; 2015 Jul; 29(7):844-9. PubMed ID: 25621993
[TBL] [Abstract][Full Text] [Related]
42. Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging.
Woo S; Cho JY; Kim SY; Kim SH
AJR Am J Roentgenol; 2015 Feb; 204(2):W168-75. PubMed ID: 25615777
[TBL] [Abstract][Full Text] [Related]
43. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.
Lebdai S; Villers A; Barret E; Nedelcu C; Bigot P; Azzouzi AR
World J Urol; 2015 Jul; 33(7):965-71. PubMed ID: 25614256
[TBL] [Abstract][Full Text] [Related]
44. Ten-year outcomes of I¹²⁵ low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan.
Hayashi N; Izumi K; Sano F; Miyoshi Y; Uemura H; Kasuya T; Mukai A; Hata M; Inoue T
World J Urol; 2015 Oct; 33(10):1519-26. PubMed ID: 25614253
[TBL] [Abstract][Full Text] [Related]
45. Abdominal obesity, hypertension, antihypertensive medication use and biochemical recurrence of prostate cancer after radical prostatectomy.
Ohwaki K; Endo F; Hattori K
Eur J Cancer; 2015 Mar; 51(5):604-9. PubMed ID: 25613441
[TBL] [Abstract][Full Text] [Related]
46. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.
Birnbaum JK; Feng Z; Gulati R; Fan J; Lotan Y; Wei JT; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2015 Apr; 24(4):677-82. PubMed ID: 25613117
[TBL] [Abstract][Full Text] [Related]
47. Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports.
Hingorani M; Dixit S; Bashir F; Butt M; Hawkyard S; Khafagy R; Robertson A
Cancer Biol Med; 2014 Dec; 11(4):277-80. PubMed ID: 25610714
[TBL] [Abstract][Full Text] [Related]
48. The place of prostate rebiopsy in the diagnosis of prostate cancer.
Vida OÁ; Pricop C; Loghin A; Chiuţu LC; Mártha O
Rom J Morphol Embryol; 2014; 55(3 Suppl):1161-6. PubMed ID: 25607400
[TBL] [Abstract][Full Text] [Related]
49. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
Cheng HH; Gulati R; Azad A; Nadal R; Twardowski P; Vaishampayan UN; Agarwal N; Heath EI; Pal SK; Rehman HT; Leiter A; Batten JA; Montgomery RB; Galsky MD; Antonarakis ES; Chi KN; Yu EY
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):122-7. PubMed ID: 25600186
[TBL] [Abstract][Full Text] [Related]
50. The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance.
Jeong CW; Park YH; Hwang SI; Lee S; Jeong SJ; Hong SK; Byun SS; Lee HJ; Lee SE
Prostate Int; 2014 Dec; 2(4):169-75. PubMed ID: 25599072
[TBL] [Abstract][Full Text] [Related]
51. Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process.
Demirkol MO; Acar Ö; Uçar B; Ramazanoğlu SR; Sağlıcan Y; Esen T
Prostate; 2015 May; 75(7):748-57. PubMed ID: 25598074
[TBL] [Abstract][Full Text] [Related]
52. Patient-reported 'ever had' and 'current' long-term physical symptoms after prostate cancer treatments.
Gavin AT; Drummond FJ; Donnelly C; O'Leary E; Sharp L; Kinnear HR
BJU Int; 2015 Sep; 116(3):397-406. PubMed ID: 25597493
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.
Cha EK; Eastham JA
Urol Oncol; 2015 May; 33(5):217-25. PubMed ID: 25596644
[TBL] [Abstract][Full Text] [Related]
54. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
55. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer.
Léon P; Seisen T; Cussenot O; Drouin SJ; Cattarino S; Compérat E; Renard-Penna R; Mozer P; Bitker MO; Rouprêt M
Urol Oncol; 2015 Sep; 33(9):384.e21-7. PubMed ID: 25595576
[TBL] [Abstract][Full Text] [Related]
56. Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer.
Martin JM; Handorf EA; Price RA; Cherian G; Buyyounouski MK; Chen DY; Kutikov A; Johnson ME; Ma CM; Horwitz EM
Med Dosim; 2015; 40(3):186-9. PubMed ID: 25595491
[TBL] [Abstract][Full Text] [Related]
57. Imaging biomarkers in prostate cancer: role of PET/CT and MRI.
Picchio M; Mapelli P; Panebianco V; Castellucci P; Incerti E; Briganti A; Gandaglia G; Kirienko M; Barchetti F; Nanni C; Montorsi F; Gianolli L; Fanti S
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):644-55. PubMed ID: 25595344
[TBL] [Abstract][Full Text] [Related]
58. Curcumin-based anti-prostate cancer agents.
Chen QH
Anticancer Agents Med Chem; 2015; 15(2):138-56. PubMed ID: 25594891
[TBL] [Abstract][Full Text] [Related]
59. Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer.
Polders DL; Steggerda M; van Herk M; Nichol K; Witteveen T; Moonen L; Nijkamp J; van der Heide UA
Acta Oncol; 2015 Jun; 54(6):839-46. PubMed ID: 25591817
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
